Introduction
Aidoc is a Tel Aviv-based clinical artificial intelligence company founded in 2016 that embeds AI into radiology and acute care workflows across nearly two thousand hospitals worldwide. Elad Walach co-founded Aidoc and serves as chief executive officer per the company’s leadership page reviewed in July 2026. Aidoc’s platform has analyzed more than one hundred twenty million patient cases and supports clinical decision-making for approximately sixty million patients annually, per the company’s June 2026 First Read announcement.
On June 25, 2026, the U.S. Food and Drug Administration granted Breakthrough Device Designation to First Read — AI designed to analyze chest radiographs and generate preliminary high-quality radiology report text — extending Aidoc’s clinically validated CARE foundation model from triage alerts into report drafting workflows where generative AI safety and clinician oversight carry legal weight.
What the company does
Aidoc provides clinical AI through its aiOS enterprise operating system — a centralized layer health systems use to deploy, manage, and scale multiple FDA-cleared algorithms within existing imaging and EMR workflows. Products span triage applications such as abdominal CT triage with FDA clearance, CARE Triage breakthrough designation from September 2025, and First Read for chest X-ray analysis and draft report generation under June 2026 Breakthrough status for four life-threatening findings.
First Read addresses imaging interpretation bottlenecks: Aidoc cited Neiman Health Policy Institute research showing outpatient imaging turnaround times more than doubled between 2014 and 2023, with emergency department CT delays adding up to one hundred fifty minutes to patient stays. By generating draft report text from imaging findings, First Read aims to return radiologist capacity to interpretation and clinical judgment rather than repetitive dictation.
Aidoc emphasizes assistive AI preserving clinician final approval — particularly important as generative reporting introduces automation bias and inconsistency risks Walach and Mount Sinai radiologist Dr. Robert Lookstein addressed in the June 2026 release.
Who it serves
Aidoc serves health systems including Sutter Health, Wellspan Health, and Mercy cited in company materials — organizations deploying clinical AI at enterprise scale rather than single-algorithm pilots. Radiology departments facing workforce shortages and rising imaging volumes represent core buyers; emergency departments benefit when chest X-ray and CT triage accelerates critical finding escalation.
Health system AI governance committees evaluate Aidoc on aiOS centralized management, FDA clearance portfolio breadth, and integration depth with PACS vendors — criteria that matter when deploying dozens of algorithms across multiple service lines.
Company background
Walach co-founded Aidoc in 2016 in Tel Aviv alongside Michael Braginsky and Guy Reiner, building from Israeli computer vision talent into a global clinical AI vendor with U.S. commercial headquarters in New York. The company raised a one hundred fifty million dollar Series E round announced in April 2026 per First Read press materials, funding continued platform expansion and hospital deployments.
Aidoc’s evolution from point-solution triage algorithms to CARE foundation model and aiOS platform mirrors industry consolidation toward enterprise AI operating layers rather than standalone apps per modality.
Product and AI capabilities
First Read builds on the same underlying architecture as Aidoc’s FDA-cleared Triage abdominal CT application — extending clinically validated foundation model training into generative report drafting. Walach stated radiology is entering a new era where safe, clinically validated AI can absorb operational burden while radiologists focus on judgment and patient care. Lookstein emphasized AI-assisted reporting must be clinically reliable and thoughtfully integrated — not merely fast.
aiOS delivers algorithms inside existing workflows, enabling health systems to govern model updates, audit usage, and manage multiple vendors through one operating layer — a deployment pattern Aidoc contrasts with bolt-on AI viewers requiring separate integration per algorithm.
Key developments
2016: Aidoc founded in Tel Aviv; Elad Walach co-founder and CEO. September 2025: CARE Triage received FDA Breakthrough Device Designation (Aidoc news timeline). June 25, 2026: First Read Breakthrough designation for chest radiograph analysis and report drafting (aidoc.com news, official source). April 2026: $150M Series E announced per First Read release.
First Read is investigational and not FDA cleared — Brel cites Breakthrough designation only, not commercial clearance. Q260882 designation covers four life-threatening chest findings per Aidoc footnote.
Why it matters
Aidoc matters because 2026 clinical AI is expanding from detection alerts into generative reporting — a workflow where every sentence carries clinical and legal weight. First Read’s second Breakthrough designation within a year shows Aidoc’s platform velocity and FDA engagement depth. Walach’s nearly two-thousand-hospital deployment footprint makes Aidoc a reference case for enterprise imaging AI scale alongside RapidAI in acute neurovascular workflows.
Radiology leaders should pilot generative reporting with explicit clinician override metrics and automation bias monitoring — Aidoc’s June 2026 release acknowledges these risks rather than treating draft reports as autonomous sign-out.
Sector context
Aidoc belongs in Brel’s AI in healthcare coverage under medical imaging AI, related to neurovascular vendors like RapidAI, data standardization platforms like Enlitic, and consumer screening companies like Ezra. Readers should distinguish Breakthrough designation from 510(k) clearance — First Read remains investigational as of June 2026.
Hospital AI committees evaluating Aidoc and RapidAI often deploy both — Aidoc for broad radiology triage and reporting, RapidAI for stroke and trauma time-critical pathways — integration through aiOS versus standalone deployment determines operational complexity.
Sources and references
Aidoc First Read Breakthrough designation news (June 25, 2026) and Leadership page.
- Aidoc — First Read FDA Breakthrough designation (aidoc.com, June 25, 2026)
- Aidoc — Leadership (aidoc.com)
Reviewed July 10, 2026. Elad Walach is co-founder and CEO. First Read investigational; not FDA cleared.